» Articles » PMID: 24346280

Effects of Low-fat and High-fat Meals on Steady-state Pharmacokinetics of Lapatinib in Patients with Advanced Solid Tumours

Overview
Publisher Springer
Specialty Oncology
Date 2013 Dec 19
PMID 24346280
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To quantify the effect of food on the systemic exposure of lapatinib at steady state when administered 1 h before and after meals, and to observe the safety and tolerability of lapatinib under these conditions in patients with advanced solid tumours.

Methods: This was a three-treatment, randomised, three-sequence cross-over study. Lapatinib was administered 1 h after a low- [B] or a high-fat [C] meal and systemic exposure was compared with that obtained following administration 1 h before a low-fat meal [A].

Results: In total, 25 patients were included, of whom 12 were evaluable for the pharmacokinetic analysis. Both low-fat and high-fat meals affected lapatinib exposure. Lapatinib AUC0-24 increased following lapatinib administration 1 h after a low-fat meal by 1.80-fold (90 % CI: 1.37-2.37) and after a high-fat meal by 2.61-fold (90 % CI: 1.98-3.43). Lapatinib Cmax increased following lapatinib administration 1 h after a low-fat meal by 1.90-fold (90 % CI: 1.49-2.43) and after a high-fat meal by 2.66-fold (90 % CI: 2.08-3.41). The most commonly occurring treatment-related toxicity was diarrhoea (8/25, 32 % CTCAE grade 1 and 2/25, 8 % grade 2) and one treatment-related grade ≥ 3 event occurred (fatigue grade 3, 4 %).

Conclusions: Both low-fat and high-fat food consumed 1 h before lapatinib administration increased lapatinib systemic exposure compared with lapatinib administration 1 h before a low-fat meal. In order to administer lapatinib in a fasted state, it is advised to administer the drug 1 h before a meal.

Citing Articles

Biopharmaceutical and pharmacokinetic attributes to drive nanoformulations of small molecule tyrosine kinase inhibitors.

Mukherjee S, Joshi V, Reddy K, Singh N, Das P, Datta P Asian J Pharm Sci. 2024; 19(6):100980.

PMID: 39640056 PMC: 11617995. DOI: 10.1016/j.ajps.2024.100980.


Effects of meal type on the bioavailability of vutiglabridin, a novel anti-obesity agent, in healthy subjects.

Won H, Yoon D, Lee S, Cho J, Oh J, Jang I Clin Transl Sci. 2024; 17(3):e13744.

PMID: 38436494 PMC: 10910614. DOI: 10.1111/cts.13744.


Dose-sparing effect of lapatinib co-administered with a high-fat enteral nutrition emulsion: preclinical pharmacokinetic study.

Zhu J, Xu G, Yang D, Song Y, Tong Y, Kong S PeerJ. 2023; 11:e16207.

PMID: 37842056 PMC: 10569162. DOI: 10.7717/peerj.16207.


The use of microtracers in food-effect trials: An alternative study design for toxic drugs with long half-lives exemplified by the case for alectinib.

van der Heijden L, Steeghs N, Beijnen J, Huitema A, Dorlo T Clin Transl Sci. 2023; 16(12):2557-2564.

PMID: 37828717 PMC: 10719472. DOI: 10.1111/cts.13647.


Reduced Fasting Duration in Cynomolgus Monkeys Enhances Animal Welfare During Toxicology Studies.

Adedeji A, Pourmohamad T, Tripathi N, Zhong S, Degner K, Zhong F Toxicol Pathol. 2023; 51(5):264-277.

PMID: 37702042 PMC: 10696910. DOI: 10.1177/01926233231193395.


References
1.
Maliepaard M, Scheffer G, Faneyte I, van Gastelen M, Pijnenborg A, Schinkel A . Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001; 61(8):3458-64. View

2.
Burris 3rd H, Hurwitz H, Dees E, Dowlati A, Blackwell K, ONeil B . Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005; 23(23):5305-13. DOI: 10.1200/JCO.2005.16.584. View

3.
Smith D, Koch K, Arya N, Bowen C, Herendeen J, Beelen A . Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2009; 67(4):421-6. PMC: 2679105. DOI: 10.1111/j.1365-2125.2009.03370.x. View

4.
Burris 3rd H, Taylor C, Jones S, Koch K, Versola M, Arya N . A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res. 2009; 15(21):6702-8. PMC: 3232441. DOI: 10.1158/1078-0432.CCR-09-0369. View

5.
Crown J, Burris 3rd H, Boyle F, Jones S, Koehler M, Newstat B . Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat. 2008; 112(2):317-25. DOI: 10.1007/s10549-007-9860-9. View